General Surgery Center, Capital Medical University Youan Hospital, 100069 Beijing, P.R. China.
General Surgery Center, Capital Medical University Xuanwu Hospital, 100032 Beijing, P.R. China.
J Environ Pathol Toxicol Oncol. 2023;42(4):47-60. doi: 10.1615/JEnvironPatholToxicolOncol.2023045721.
Hepatocellular carcinoma (HCC) is the predominant pathological type of liver cancer. Several therapeutic treatments, including sorafenib and regorafenib, have only modestly improved survival in patients with HCC. The aim of this study was to investigate the expression profiles and the regulation of competitive endogenous RNAs (ceRNAs) of the sorafenib-related target genes in HCC. Based on clinical information and expression profiles of HCC clinical samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, shared differentially expressed genes (DEGs) were analyzed and identified. Sorafenib-associated DEGs (SADs) were obtained by intersecting the DEGs with the sorafenib target genes from SuperTarget database. The expression patterns of SADs were verified in the Oncomine database. The biological functions of the SADs were annotated by gene set enrichment analysis (GSEA). In addition, a ceRNA network associated with SADs was constructed. Long non-coding RNAs (lncRNAs) in network that were significantly associated with overall survival were identified as prognosis of patients by Cox regression analysis. Finally, the expression levels of prognostic genes in HCC tissues and cell lines were verified using qRT-PCR. Gene expression differential analysis yielded a total of 146 common DEGs were obtained, including 21 upregulated and 125 downregulated DEGs. Among them, ten SADs were detected to be differentially expressed between tumor and normal tissues, including AXL, CYP2C19, CYP2C8, CYP2C9, CYP3A4, FGFR2, GMNN, PDGFRA, and TTK. GSEA analysis grouped them into three categories by function. The first category (CYP2C19, CYP2C8, CYP2C9 and CYP3A4) and second category (GMNN, TTK and EGER2) had the opposite roles in the enriched terms and pathways, while the third class (AXL and PDGFRA) has enrichment terms and pathways that intersect with those of the first and second categories. A ceRNA network associated with SADs was also constructed including 49 lncRNAs, 14 miRNAs, and 8 mRNAs. Three of these lncRNAs, SNHG7, GAS5 and HCP5, were found upregulated in HCC tissues and to be independent predictors in HCC patients. Significant correlations were found in expression between the prognostic lncRNAs and SADs. Ten SADs were systematically identified using expression data from HCC and normal tissues from TCGA and GEO datasets. GSEA analysis provided us with insight into the function of SADs. In the future, we will continue to explore the mechanisms of coordinated regulation of SADs-related prognostic lncRNAs and SADs at the ceRNA axis level and their potential functions in the development of HCC.
肝细胞癌(HCC)是肝癌的主要病理类型。索拉非尼和瑞戈非尼等几种治疗方法仅略微改善了 HCC 患者的生存。本研究旨在探讨 HCC 中与索拉非尼相关的靶基因的竞争内源性 RNA(ceRNA)的表达谱和调控。基于癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)临床信息和 HCC 临床样本的表达谱,分析和鉴定了共享的差异表达基因(DEG)。通过将 DEG 与 SuperTarget 数据库中的索拉非尼靶基因相交,获得与索拉非尼相关的 DEG(SAD)。在 Oncomine 数据库中验证 SAD 的表达模式。通过基因集富集分析(GSEA)注释 SAD 的生物学功能。此外,构建了与 SAD 相关的 ceRNA 网络。通过 Cox 回归分析,确定网络中与总生存期显著相关的长非编码 RNA(lncRNA)作为患者的预后标志物。最后,使用 qRT-PCR 验证 HCC 组织和细胞系中预后基因的表达水平。基因表达差异分析共获得 146 个共同 DEG,包括 21 个上调和 125 个下调 DEG。其中,在肿瘤组织和正常组织之间检测到十个 SAD 差异表达,包括 AXL、CYP2C19、CYP2C8、CYP2C9、CYP3A4、FGFR2、GMNN、PDGFRA 和 TTK。GSEA 分析按功能将它们分为三类。第一类(CYP2C19、CYP2C8、CYP2C9 和 CYP3A4)和第二类(GMNN、TTK 和 EGER2)在富集术语和途径中起相反的作用,而第三类(AXL 和 PDGFRA)具有与第一类和第二类重叠的富集术语和途径。还构建了一个与 SAD 相关的 ceRNA 网络,包括 49 个 lncRNA、14 个 miRNA 和 8 个 mRNA。其中三个 lncRNA,SNHG7、GAS5 和 HCP5,在 HCC 组织中上调,并成为 HCC 患者的独立预后标志物。在预后 lncRNA 和 SAD 之间的表达中发现了显著相关性。使用 TCGA 和 GEO 数据集的 HCC 和正常组织的表达数据,系统地鉴定了十个 SAD。GSEA 分析为我们提供了对 SAD 功能的深入了解。在未来,我们将继续探索 SAD 相关预后 lncRNA 和 SAD 在 ceRNA 轴水平上的协调调控机制及其在 HCC 发展中的潜在功能。